臨床婦人科産科71巻1号

2017年01月発行

合併増大号　今月の臨床 性ステロイドホルモン研究の最前線と臨床応用 臨床総論 : 製剤の種類と特徴

エストロゲン製剤

著者： 安井敏之¹

所属機関： ¹徳島大学大学院医歯薬学研究部生殖・更年期医療学分野

ページ範囲：P.36 - P.44

●エストロゲン製剤は，種類，投与経路，投与量によって作用の強弱が異なる．

●肥満やメタボリック症候群，胆石症，慢性肝疾患を合併した女性では経皮製剤を考慮する．

●更年期障害の程度，年齢，HRTの目的などを考慮し，投与量を選択する．

参考文献

1）安井敏之 : 「ホルモン補充療法ガイドライン2012年度版」HRTのレジュメと使用される薬剤の特徴．日産婦会誌65 : N60─70, 2013

2）Yasui T, et al : Combination of automatic HPLC-RIA method for determination of estrone and estradiol in serum. J Clin Lab Anal 13 : 266─272, 1999

3）Kuhl H : Pharmacology of estrogen and progestogens : influence of different routes of administration. Climacteric 8 : 3─63, 2005

4）北脇　城 : OC・LEPの種類と特徴．産と婦83 : 127─132, 2016

5）日本産科婦人科学会・日本更年期医学会 : ホルモン補充療法ガイドライン2012年度版．pp10─16，pp41─43，pp66─74，日本産科婦人科学会，2012

6）Sweetland S, et al : Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thrombo Haemost 10 : 2277─2286, 2012

7）Renoux C, et al : Transdermal and oral hormone replacement therapy and the risk of stroke : a nested case-control study. BMJ 340 : c2519─2525, 2010

8）安井敏之，他 : HRTの慎重投与への対応 慢性肝疾患・胆嚢炎および胆石症の既往．産と婦80 : 1609─1616, 2013

9）寺内公一 : エストロゲンのベネフィットやリスクは経口投与と経皮投与とで異なりますか．産と婦81 : 1443─1451, 2014

10）Barbieri RL : Hormone treatment of endometriosis : the estrogen threshold hypothesis. Am J Obstet Gynecol 166 : 740─745, 1992

11）Jane FM, et al : A practitioner's toolkit for managing the menopause. Climacteric 17 : 564─579, 2014

12）Baber RJ, et al : 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 19 : 109─150, 2016

13）Matsui S, et al : Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women. Climacteric 17 : 191─196, 2014

14）Terauchi M, et al : Effects of oral estradiol and leveonorgestrel on cardiovascular risk markers in postmenopausal women. Arch Gynecol Obstet 285 : 1647─1656, 2012

15）Mizunuma H, et al : Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. Climacteric 13 : 72─83, 2010

16）Speroff L, et al : Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 88 : 587─592, 1996

17）Evans SF, et al : Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol 44 : 79─84, 1996

18）Utian WH, et al : Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system（Esclim） compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am J Obstet Gynecol 181 : 71─79, 1999

19）Mizunuma H : Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms. Climacteric 14 : 581─589, 2011

20）Stegeman BH, et al : Different combined oral contraceptives and the risk of venous thrombosis : systemic review and network meta-analysis. BMJ 347 : f5298, 2013

21）Beaber EF, et al : Recent oral contraceptive use by formulation and breast cancer risk among women 20-49 years of age. Cancer Res 74 : 4078─4089, 2014

22）Scholes D, et al : Oral contraceptive use and bone density change in adolescent and young adult women : A prospective study of age, hormone dose, and discontinuation. J Clin Endocrinol Metab 96 : E1380─E1387, 2011